ArticleCancer cell2021
Lorlatinib in ALK-Rearranged Lung Cancer.
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Comparing Genomic Profiles ofGlobal medical genetics · 2024Article
- Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study.Oncology letters · 2024Article
- Clinical characteristics and progression of pre-/minimally invasive lung adenocarcinoma harboringTranslational lung cancer research · 2023Article
- Genomic Features of Solid Tumor Patients HarboringFrontiers in oncology · 2022Article
- Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion.Annals of translational medicine · 2021Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.